Glucocorticoid Dosing and Outcomes in ANCA-Associated Vasculitis With Kidney Involvement.

ABSTRACT:

Introduction

There may be reservations about the guideline-recommended use of reduced glucocorticoid (GC) therapy in severe ANCA-associated vasculitis (AAV). We examined differences in outcomes based on oral GC use during induction therapy for AAV with kidney involvement.

Methods

We conducted a single-center, retrospective cohort study (2010-2023) of patients with biopsy-proven kidney involvement from AAV. Patients were divided into eras 2020 onward (reduced-GC) versus pre-2020 (standard-GC) according to practice shift after adopting a reduced-GC regimen. The primary outcome was the composite of end-stage kidney disease (ESKD) or death within 12 months postbiopsy. Secondary outcomes included serious infection, clinical remission, and change in estimated glomerular filtration

SUBMITTER: Salman M 

PROVIDER: S-EPMC12545648 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature